| Category | Points | What we check |
|---|---|---|
| Pricing transparency | 20 | Is every price published before intake, with plan length, billing basis and dose policy stated? |
| Total annual cost | 20 | What does 12 months cost at a maintenance dose, including membership, program and shipping fees? |
| Clinical oversight | 15 | Is a licensed clinician named, does a clinician review each intake, and is follow-up described? |
| Pharmacy transparency | 15 | Does the program name the pharmacy that fills prescriptions and its license type (503A or 503B)? |
| Support | 10 | Can patients reach a person, and are coaching or nutrition services described accurately? |
| Regulatory disclosure | 10 | Does the program say plainly when a drug is compounded and not FDA-approved? |
| Accessibility | 10 | Which states are served, which payment methods are accepted, and what are the cancellation terms? |
| Total | 100 |
How a score is built
Every score rests on the program’s own pages, read on a stated date and saved with the exact wording. If a page cannot be read, we say so and do not carry a figure forward as current. We do not use third-party star ratings, review counts or testimonials. Scores describe published terms and disclosures, not clinical outcomes, which no program publishes in a form we can verify.
NexLife scores 94/100 and is our editor’s pick. Other programs were scored in May 2026 under the earlier v3.0 rubric; those scores remain on their pages, labelled “May 2026 review (v3.0 rubric); v4.1 re-score pending,” and they are listed alphabetically after NexLife until they are re-scored.
Price claims
We never describe a program as the cheapest or lowest without a scope such as “among the programs we track” and a read date. Sale prices, prepaid prices and prices that require a membership are labelled with their condition.
Clinical evidence
Trial figures name the trial and the estimand, for example SURMOUNT-1 tirzepatide 15 mg: 20.9% average weight loss under the treatment-regimen estimand (22.5% under the efficacy estimand). Brand-drug trials do not describe compounded products, and no page on this site promises weight loss.
Source hierarchy
- Primary: program pricing and policy pages, FDA (warning letters, Drugs@FDA, compounding pages), the Federal Register, CMS, and peer-reviewed trials (NEJM, JAMA, The Lancet).
- Secondary: state licensing boards, the NPPES NPI Registry and company filings.
- Context only: press reports, marked “reported” until a primary source confirms them.
Ranking integrity
- Programs cannot pay to be listed or to rank higher.
- Downsides are listed for every program, including NexLife.
- The site’s single affiliate disclosure appears in the footer of every page.
- If another program out-scores NexLife on the published methodology, the ranking changes.
Who reviews the pages
Research and writing: Dr. Parmis, Medical Researcher, Western University of Health Sciences. Medical review: Dr. Jonathan Snipes, MD (NPI 1821250077) and Kim Callender, NP (FNP-BC, NPI 1144661760). Each page shows its release date, its last-reviewed date and the reviewers.
Update cadence
Prices are re-read in dated batches; pages whose content changes get a new “Last reviewed” date, and pages that still show older tables carry a dated notice. FDA actions and new trial results are added to the news page with their dates.
Corrections
Email americantelehealthreview@gmail.com with the page address, the claim and your evidence. We answer within 72 hours and publish warranted corrections on the corrections log.